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on around 40-50% of imported products while the medical electronics ($1.57 billion), 
hospital equipments ($0.39 billion), implants ($0.20 billion) and diagnostics ($0.09 
billion) categories on around 85-90%. Due to more dependency on imported products 
as well as absence of regulations for prices in India, doctors, hospitals and retailers 
overcharged the patients almost three to four times for certain devices e.g. Drug 
eluting stents (DES) manufactured by Abbott imported at $640 and sold at $2000, 
a mark-up of over 250% and that manufactured by Medtronics imported at $485 
and sold at $2600, a mark-up of more than 400%. Recognising this policy deficit, 
the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, 
has published draft proposals which is National Medical Device Policy-2015 for 
the medical devices approval & pricing regulations. These proposals have recom-
mended creating an autonomous body, the National Medical Devices Authority 
(NDMA) for pricing control of medical devices by including them under the Essential 
Commodities Act or through a Medical Devices Prices Control Order(MDPCO) 
and creating a separate pricing division in the National Pharmaceuticals Pricing 
Authority(NPPA). Ispor-India chapter has developed Pharmacoeconomic guidelines 
which will also include the above mentioned devices and the same will be presented 
in this presentation along with our survey data.
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Recently, the need for health services has increased gradually and the limita-
tions in sources allocated for this area have been recognized.According to Danzon 
(2001), arrangements towards controlling the expenses through price,profit con-
trols and reimbursement methods This study examines;current situation in 
Turkey and Ukraine, pharmaceutical pricing methods, reimbursement methods 
and basic health indicators within the scope of changing pharmaceutical poli-
cies in Turkey and Ukraine. It was detected that the pharmaceutical pricing in 
Turkey has been performed on the basis of the reference pricing system that takes 
Italy,Portugal,Spain,Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. In Ukraine there are margin control 
and reference pricing methods only for the medicines that may be public purchased 
and are included in the National list of medicines and the list of medicines “On the 
procedure of procurement of medicines by health institutions financed from the 
public budget”. Reimbursement method was applied only for one pilot project on 
antihypertensive medicines in 2012 because state health insurance system has 
not yet implemented. Due to the resolution of Cabinet of ministers of Ukraine “On 
reference pricing for medicines and medical products, purchased by the state and 
local budgets reference pricing is implemented for medicines, which are included in 
the list of medicines that have margin control and may be purchased within public 
budgets. Reference pricing is based on the international comparison with prices in 
mainly eastern Europe countries. Coverage of government was 13% of the Ukrainian 
pharmaceutical market The reimbursement system of Turkey has been changed 
numerous times and the discount rates has incrementally risen. Ukraine has just 
began implementing pricing and reimbursement for medicines. It is understand that 
Turkey has been done policies already but Ukraine has just began implementations. 
Our study shows impact of Turkish reforms and expected from Ukraine.
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Objectives: Health Professionals in Africa in an attempt to improve healthcare 
delivery have brought up well thought out ways to offer better health care service, 
but for their lack of involvement in Politics and Legislation in their countries, efforts 
to implement their proposals have been met with brick walls. The Objective of this 
conceptual paper is to emphasis the need for Healthcare providers to be involved in 
Policy making in their countries, to champion health care policies that will improve 
health care delivery. MethOds: Using Nigeria as case study. I sort the views of 
several health professionals through their articles on Improving Healthcare delivery 
in Nigeria published in popular Journals and magazines. I consulted magazines and 
Journals from more advanced countries to seek out ways through which they have 
improved their health care system. Results: Of all the views presented by these 
health professionals (Pharmacist and Medical Doctors), most pointed towards the 
role of the government in improving the healthcare sector, others suggested a need 
for health professionals to be involved in Politics without emphasizing on it. While 
in my analysis of the systems in the developed countries, I discovered that health-
care providers were involved in the government not as executive but as legislatures, 
this way they sponsor health related bills and policies and were able to improve the 
value of healthcare delivery. cOnclusiOns: To improve healthcare delivery and 
patient care in Africa, Health care givers (pharmacist and doctors) should be part 
of the countries policy makers (legislatures) so as to drive the needed transforma-
tion in the health sector.
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Nepal is a topographically vulnerable country for many life threatening disasters 
like earthquake, landslides, avalanche, floods etc. Health care policy should focus on 
the disaster management plan and quick relief programs following major disasters. 
According to National consensus, 8151 people have been killed and 17,886 left injured. 
Nepal’s earthquake economic toll is massive in the health sector too. Many hospitals 
on media to dispute sofosbuvir price considered as scandalous, while compliant 
with French regulation. French Health Minister organized a European coalition to 
control its price. Under tremendous media, political and administrative pressure, 
the manufacturer accepted significant price decrease, early entry agreement in 
France and later in most EU countries. Following this saga, to ensure drug budget 
will remain under control, most EU countries issued regulation or law to cap drug 
budget expenditure for HCV. cOnclusiOn: This case highlights limit of current 
pricing policies which are unable to match affordability and drug prices. Even 
if cost effectiveness remains important information for efficiency assessment, 
sofosbuvir case confirms the inability of cost-effectiveness analysis to address 
affordability issue. Budget impact in supporting decision making will become 
more and more critical in the future.
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bAckgROund: Cancer imposes enormous financial burden to society. Direct medi-
cal costs were estimated at around € 51 billion across European (EU) countries (2009) 
and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” 
has been first reported by US academic oncologists, Zafar and Abernathy in 2013. 
It refers to financial distress linked to out-of-pocket payments of costly oncology 
drugs (OD). This critical concept led to the development of a patient-reported out-
come questionnaire by de Souza et al. This conceptual research aimed to address 
aspects of oncology drug financial toxicity (ODFT) and how the US and European 
Union countries cope with high OD prices. discussiOn: ODFT has been reported 
to affect patient’s quality of life and treatment adherence. In US, ODFT is related to 
the positioning in specialty care tier (fourth or fifth tier), leaving a high co-pay for 
the patients. Moreover, 13% of the US population is uninsured (2013). This issue is 
not new; in 2007, a study reported that 16% of oncologist did not propose expensive 
products to some patients based on their perception of patient affordability. In EU, 
the coverage system is quite different and operates as an on/off system, protect-
ing patients from ODFT. Patients are either 100% covered for all reimbursed drugs 
(France, UK, Germany, Spain, Italy), or drugs are not recommended/reimbursed and 
then not proposed to the patients nor requested by the patients. The level of avail-
ability of these treatments might substantially differ between countries; high access 
of cancer drugs seen in France and Germany, while more restricted access seen 
in Spain, Italy and the UK. cOnclusiOns: EU inhabitants will remain protected 
from ODFT as long as reimbursement process remains an on/off system (100% or 
0% coverage) and off-reimbursement use is exceptional. ODFT will remain specific 
to the US and possibly to emerging countries.
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bAckgROund: The South African Pharmacoeconomic Guidelines were published 
in February 2013, with the intention for application to newly approved medicines in 
the privates sector. However, uptake has been poor and the number of submissions 
negligible. Objectives: This study aims to examine the pharmacoeconomic guide-
lines in the context of existing legislation, policy and incentives in the private sector 
in South Africa to make explicit the reasons for the poor uptake and challenges to 
implementing the guidelines. MethOds: A review of existing legislation regulating 
reimbursement of medicines in the private sector was undertaken in relation to 
the implementation of the guidelines, as well as interviews with key stakeholders 
in the pharmaceutical industry, ministry of health and health insurance industries 
to understand attitudes to and challenges to adopting the guidelines submission 
criteria and results. Results: Existing legislation means that results of pharmaco-
economic submissions are not enforceable – funders are not required reimburse for 
products should the ministry of health evaluations process deem them cost-effec-
tive. Pharmaceutical companies are thus at risk of a negative finding on reimburse-
ment with no assurance that a positive finding will improve reimbursement for new 
products. As submission is currently not mandatory, this is something they will be 
unlikely to do. The level of strict application or flexibility within the requirements 
of the guidelines is also not clear. cOnclusiOns: Uptake and engagement with the 
South African Pharmacoeconomic Guidelines has been poor, with no submissions 
formally evaluated since the guidelines were finalised. Several existing policy and 
legislative barriers exist which make the success of these guidelines in this current 
environment unlikely. Building capacity for submitting analyses as well as within 
the ministry of health to evaluate submissions will be critical.
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In India, medical device industry is a multi-product industry covering the entire 
gamut from disposable gloves and syringes to high-end machines like CT scans 
and robotic surgery machines and worth $5 billion approximately growing at a 
Compound Annual Growth Rate (CAGR) of 15%. Over 75% of medical devices market 
is dependent on imports, mostly by multinationals that have no manufacturing facil-
ity in India. According to a survey conducted by us, the disposables ($1.57 billion), 
consumables ($0.83 billion) and surgical instruments ($0.06 billion) market depends 
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Kazakhstan is an upper-middle-income country with per capita GDP of nearly 
US$13 thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified 
National Health System) – aims to deliver healthcare coverage to the whole popu-
lation. The political desire of authorities to provide broader access to healthcare 
for its populations, along with the growing prevalence of non-communicable dis-
eases (NCDs) such as cardiovascular disease, cancer and diabetes, are placing a 
strain not only on government budget but also on the healthcare infrastructure 
in Kazakhstan. Increasing life expectancy is giving rise to the greater burden 
associated with ageing populations, while governments struggle to balance grow-
ing costs with a need to expand healthcare provision to all. At the heart of any 
cost-containment strategy is a set of tools, ranging from complex risk-sharing 
schemes and health technology assessment (HTA) through to more simplistic 
mechanisms, such as prescribing controls and mandatory price cuts. Analysis of 
cost-management trends in Kazakhstan, relative with international experience, 
suggests a leaning towards less complex approaches. One reason for this is that 
before being able to even contemplate more sophisticated initiatives, governments 
must first address basic infrastructure needs. These include having sufficient doc-
tors and clinics to diagnose and treat patients. There is growing appreciation that 
cost containment can only be effective when implemented in a systematic man-
ner. Kazakhstan already have informal guidelines in place and are now consid-
ered «mature» markets in terms of HTA adoption. Despite the obvious challenges, 
some would argue that the time for HTA has arrived in Kazakhstan. Implemented 
correctly, it can play a role in the future of the region, not only as a key compo-
nent of cost containment but also as a pivotal enabler for the efficient use of 
resources, as governments look to provide broader access to affordable healthcare 
for all.
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Objectives: This conceptual paper aims to build a roadmap to reach integrated 
healthcare (HC) system in Egypt for optimum efficiency and utilization of resources 
among the different insurance bodies. The roadmap will help fill in the gaps 
evolved from the fragmented system having 5 different types of insurance cov-
erage. MethOds: Gap analysis between the desired integrated HC system that 
achieves; Equity, Solidarity and Free access to entire population, and the current 
situation of the HC system which was obtained from interviews and discussions 
with the HC payers and decision makers inside the public sector. Results: A 
ten year roadmap was built with eight action steps that were identified to reach 
integrated HC system: 1- Task Force Committee: from inside and outside the 
public sectors, 2- Research and Data centre: responsible for Epidemiological and 
Pharmacoepidemiological studies, 3- Prioritization plan: prioritize coverage plan 
based on budget and strategic diseases burden , 4- Treatment Protocols Flowchart: 
ensuring unified treatment guidelines across different HC bodies 5-Unique 
Patient ID: thus all insured patients are traceable without double counts, 6- Health 
Information System: connecting all HC units for optimum resources utilization, 
7- Primary Care Physicians Development Plan: continuous education programs 
for optimizing their utilization and freeing time to the over-utilized special-
ists, 8- Health Economics Unit: that will be the nucleus of establishing a Health 
Technology Assessment body responsible for economical strategic planning of the 
HC. RecOMMendAtiOns: Although some action steps were taken in some of the 
mentioned points however they were executed as separate initiatives inside the 
public sector; therefore it’s of high importance that the taskforce committee takes 
the accountability of executing the project as a single mission, and make sure the 
executed action steps are utilized and integrated with the rest of action steps as 
per the roadmap timetable.
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Objectives: The health care system reforms, which in many countries, par-
ticularly in the Eastern Europe, started in the 1990s, affected Latvia as well. The 
directions of the reforms can be divided into two basic segments – health care 
system organisation and health care system financing. Within the framework of 
this research, the author evaluates the health system research opportunities to 
assess the efficiency of the health care system reform in Latvia. MethOds: To 
achieve the goal of the research, the methods of the theoretical research are used 
alongside the methods of empirical research. The methods of statistical analy-
sis and methods of economic analysis are used for data processing and analy-
sis. Results: To perform the research, the author uses a three-level performance 
evaluation model based on macro-level evaluation, meso-level evaluation, and 
micro-level evaluation. The appropriate measures of the macro impact results, 
policy outcomes and performance outputs are defined to evaluate the effective-
ness of the performed health care system reform. The author assumes that the 
macro impact results are specified for public health, the policy outcomes are 
determined for the health care, as well as the pharmacy, while the performance’s 
outputs are representative for all areas. cOnclusiOns: The general conclusions 
show, for example, that the economic efficiency of the reimbursement system is 
sufficient and at the same time there is a tendency to move towards technical 
efficiency rather than total economic efficiency (technical and allocative effi-
ciency). The allocative efficiency in health economics is also associated with the 
market efficiency and effectiveness of the treatment process. However, the author 
notes that there are no perfect competition market conditions for health care 
products and services, so it is necessary to use alternative methods of economic 
analysis.
are completely damaged where others have been left with endangered to work in. 
The damaged infrastructure has left with inability to store essential drugs and vac-
cines. The cost of building new health care facilities is expected to reach billions of 
dollars. The cost required for the acute trauma is estimated very high. As homeless 
people are living in improper shelter, they have been presenting with other health 
related problems. For the short term relief, disaster management team should be 
formed in major government hospitals and medical colleges taking help of army and 
police health care personnel. Immediate enrolment of medical officers at the level 
of primary health centers should be done. A blend with major government and non-
government organizations like International Red Cross, United Nations Organization, 
World Health Organization, USAID etc. should be made to meet the health care equip-
ment, trained manpower and all other expenses. For the long term relief, trauma cent-
ers should be established in regional levels. As most of the remote villages even don’t 
have primary health centers, the health and sub health posts should be upgraded to 
meet the demands. Health posts and sub health posts should engage at least medical 
officers backed up by supportive staffs and basic investigations.
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bAckgROund: Market access for pharmaceuticals is evolving in a fast-changing 
environment : (1)Pressure of European Union (EU) Member States (MS) on health 
insurance budgets; (2) Dramatic technological advances; targeting new biological 
pathways, advanced therapy medicinal products, personalized medicines, expansion 
of digital medicine; (3) Initiatives from regulators and payers to develop synergies, 
e.g., collaborations between HTA agencies and multi-HTA/parallel early advice; (4) 
Increased payer risk-aversion and increasing products with limited information at 
launch; (5) Healthcare organisations moving towards integrated healthcare services 
(6) Ageing population and growing prevalence of chronic conditions, co-morbidi-
ties, and life threatening diseases; (7) Increased access inequity between EU MS. 
discussiOn: Cost-containment measures will increase under close supervision 
of parliaments. Fast development of electronic communication will allow online 
monitoring of drug utilisation. Adaptive licensing and limited evidence at time of 
launch will lead to generalization of coverage with evidence development. A more 
pragmatic approach in clinical trial designs should be considered to cope with con-
comitant development of companion diagnostics, segmentation of treated patients 
with targeted therapies; adaptive pathways should evolve from pilot to standard 
approach. Post-launch observational studies will become unavoidable to meet regu-
lators and payers’ expectations. Pan-European HTA coordination could lead to one 
single European HTA body assessing drugs prior to national HTA and pricing and 
reimbursement process. Managed entry agreements, ambulatory DRG, and bundled 
payments might become standard models. Integrated health services will expand, 
shifting payers role to health care providers. Differential pricing will address access 
inequity. cOnclusiOn: Sustainability of healthcare systems will remain at the 
heart of drug funding decisions. Drug market access will evolve through extended 
collaborations and interactions between key stakeholders. Drug licensing, pricing 
and reimbursement decisions will be increasingly coordinated to enable fast patient 
access to innovative therapies. Real-world data will be central to switch from initial 
restricted access to progressive wider coverage.
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bAckgROund: Adaptive pathways (AP) are prospective planned approaches to regula-
tion and coverage of drugs. Through iterative phases of evidence gathering, it aims to 
reduce uncertainties while balancing timely access for patients and level of available 
evidence. The concept assumes that all phases from development to clinical routine 
use through reimbursement are integrated. If AP did develop from regulatory per-
spective, many payers remain resistant. The aim of this research is to discuss payer’s 
position on AP. discussiOn: Payers show an increasing resistance to uncertainty and 
their decisions are mainly driven by evidence robustness. Regulators are integrating 
foregone alternative treatment opportunities in decision making and increasingly 
registering drugs with limited evidence and larger benefit estimates. Time from devel-
opment initiation to marketing authorization (MA) decreases overtime (compassionate 
use, accelerated assessment, conditional MA, MA under exceptional circumstances); 
On the opposite, time from MA to reimbursement expand with an increasing number 
of products denied reimbursement due to limited evidence. This gap between regula-
tors and payers continues to increase and AP may widen this gap. While managed 
entry agreements were thought to help managing uncertainty, it happens, in most of 
the cases, to be used as disguised cost-containment tools. Only coverage with evidence 
development (CED) with escrow agreements remain an appropriate tool to address 
uncertainty, but is rarely used. The difficulty to reverse reimbursement decision makes 
payers very sensitive to uncertainty. AP is unlikely to address the payers concern unless 
they are directly involved in identifying risk, designing mitigation plan, and moni-
toring the uncertainty. cOnclusiOn: AP may contribute to widen the gap between 
regulators and payers. Only CED with escrow agreement may be an appropriate tool 
to address payers’ uncertainty. However, AP pilot projects with expected high benefit 
will exercise pressure on payers to issue reimbursement.
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